REGLAN (metoclopramide hydrochloride) by ANI Pharmaceuticals is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. First approved in 1980.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
REGLAN (metoclopramide HCl) is an oral small-molecule dopamine antagonist that enhances upper GI motility and prevents nausea/vomiting by blocking chemoreceptor trigger zone stimulation. It accelerates gastric emptying and increases lower esophageal sphincter pressure, making it effective for gastroparesis, gastroesophageal reflux, and post-operative nausea. The drug sensitizes GI tissues to acetylcholine while antagonizing central and peripheral dopamine receptors.
Late-stage lifecycle with minimal Part D utilization (155 claims, $88K spending in 2023) indicates shrinking market; expect consolidation of commercial support and shift toward generic management focus.
CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…
Worked on REGLAN at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on REGLAN offers limited career trajectory given its LOE-approaching status and minimal linked job openings (0 recorded). Roles focus on defending market share, managing generic competition, and optimizing supply chain rather than growth or innovation—suitable for professionals seeking stability or niche expertise in established-product management.